WHAT PEOPLE ARE SAYING ABOUT… GLP-1s & Endometriosis

The first entry in a new ESSI series, where we step outside the exam room and listen to what endometriosis patients are actually talking about online — then hold it up against the data.

Why This One, First?

If you spend any amount of time in the corners of the internet where endometriosis patients gather — the r/endo subreddit, private Facebook groups, TikTok reels captioned “two weeks on Mounjaro and my endo belly is gone,” Instagram carousels of before-and-after bloat photos — you already know that GLP-1 medications have become one of the most discussed, most hoped-for, and most debated topics in the community right now.

And until recently, all we had were stories.

Now we have the first international survey specifically designed to measure what this class of drugs is actually doing for people living with endometriosis. The results are worth looking at carefully — not because GLP-1s are a cure (they are not), but because the signal is strong enough that no serious endometriosis clinician can afford to ignore it.

Here is what the community has been saying. And here is what the data now says back.

What the Community Has Been Saying

Going back through thousands of posts, comments, and patient-shared stories across Reddit, TikTok, Instagram, and private support groups, the same handful of themes keep surfacing. Summarized without naming anyone, and anonymized as community patterns rather than individual voices:

• The bloating relief story. The single most-repeated experience — by a wide margin — is the disappearance of so-called “endo belly”. Patients describe waking up flat, eating a full meal without distending to a size that looks pregnant, and wearing clothes they had given up on. For many, this is what kept them on the medication even when the other side effects were uncomfortable.

• The “my period changed” story. A smaller but consistent group describes periods that became shorter, lighter, or less painful within a few cycles of starting a GLP-1. Some say they stopped needing the rescue medications they had relied on for years.

• The quiet wins. Lower back pain that patients did not even realize was endometriosis-related, easing up. Flare days that felt less catastrophic. Being able to exercise again. Sleeping through the night during the worst week of the cycle.

• The microdosing trend. A subgroup — especially people who are not overweight — describes deliberately using GLP-1s at a lower-than-standard dose, purely for the anti-inflammatory and bloating effects, with weight loss treated as an unwanted side effect they are actively trying to minimize.

• The “it came back” story. One of the most important themes, and one that does not always get airtime in the more enthusiastic corners of the internet: what happens when people stop the medication. Many describe symptoms returning within weeks of their last dose.

• The side-effect story. Nausea, most commonly. Constipation. Food aversions. And an honest minority who say the GI side effects were so close to their existing endo-belly symptoms that they could not always tell what was the drug and what was the disease.

What the Data Now Says

An international survey led by Dr. Mathew Leonardi’s team at McMaster University asked people with confirmed or suspected endometriosis who had used a GLP-1 receptor agonist to report their experience on a structured seven-point scale. The headline findings line up almost point-for-point with the community themes above:

• 64.6% reported improvement in at least one endometriosis-related symptom.

• 33.7% reported complete resolution of at least one symptom.

• Pelvic pain, bloating, lower back pain, and multiple quality-of-life domains all showed statistically significant improvement (p < 0.001 — meaning the changes are very unlikely to be chance).

• Use of rescue medications and alternative therapies dropped significantly.

• Mean weight loss was about 12 kg, and greater weight loss correlated with greater improvement in overall quality of life.

• 60.3% of those who stopped the medication reported their symptoms returned.

• 75.2% were on semaglutide (Ozempic, Wegovy, Rybelsus) and 19.9% on tirzepatide (Mounjaro, Zepbound).

The Side of This That Doesn’t Get Enough Airtime

A separate analysis of nearly 30,000 GLP-1 users on Reddit found that roughly two-thirds reported at least one gastrointestinal side effect. Nausea topped the list at nearly 37%, followed by vomiting, constipation, and diarrhea. For someone with endometriosis — whose baseline already includes bloating, nausea, bowel pain, and constipation — those numbers matter. Some patients find the overlap manageable and worth the trade-off. Others find it intolerable. There is no reliable way to predict which group you will be in until you try.

A few more things the community discussion tends to underplay:

• GLP-1 medications are not FDA-approved to treat endometriosis. Any use for this purpose is off-label.

• They are not a replacement for excision surgery when surgery is indicated. Lesions do not disappear because inflammation is quieter.

• The 60.3% recurrence rate after stopping suggests that for most people these drugs are a management tool, not a one-time fix — a very different medical and financial commitment than the community sometimes frames it as.

• Fertility planning matters. Current guidance recommends a washout period before trying to conceive.

• Effects on oral hormonal contraceptives may be altered by delayed gastric emptying, which is directly relevant for patients using the pill as part of their endometriosis management.

What This Actually Means

The signal is real, the mechanism is biologically plausible, and the patient-reported outcomes from the first international survey line up remarkably well with what the community has been saying on its own for two years. Endometriosis is, at its core, a chronic inflammatory disease with metabolic crosstalk. GLP-1 receptor agonists happen to be one of the most potent systemic anti-inflammatory tools modern medicine has, with direct effects on the immune-signaling pathways implicated in endometriosis lesions. It would be more surprising if they did nothing than if they helped a meaningful subset of patients.

What we do not yet have are randomized controlled trials specifically for endometriosis pain. What we do not yet have are long-term safety data for patients using these drugs for a decade or more for a non-diabetes, non-obesity indication. What we do not yet have is clarity on who, exactly, is most likely to benefit.

If you are considering a GLP-1 as part of your endometriosis care, the conversation should happen with a specialist team that understands both your disease and your metabolic picture — not through a telehealth prescription based on a TikTok.

This article is part of ESSI’s “What People Are Saying About…” series, an ongoing look at the conversations endometriosis patients are having online and how those conversations compare to the emerging evidence. Nothing in this piece is medical advice.

Sources

• Leonardi M et al. Effects of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) on Endometriosis Symptoms Management and Quality of Life: An International Survey Study. McMaster University, preprint (2026).

• Self-Reported Side Effects of Semaglutide and Tirzepatide in Online Communities (Reddit cohort, n = 29,172, May 2019–June 2025).

• Stuparich M. GLP-1 Agonists and Endometriosis Care. ESSI / internationalendo.com (2025).

• Treating Endometriosis Inflammation with GLP-1s. ESSI / internationalendo.com (2025).

• Krasnyi A et al. Ghrelin, Glucagon, Visfatin and GLP-1 in Peritoneal Fluid of Women with Endometriosis. Int J Mol Sci (2022).